Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

986
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
986
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

1.1K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
1.1K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

913
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
913
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
Peripherally and Centrally Acting Muscle Relaxants: A Comparison01:09

Peripherally and Centrally Acting Muscle Relaxants: A Comparison

4.5K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Orthostatic Myoclonus-Clinical and Electrophysiological Features in a Large Retrospective Cohort.

Movement disorders clinical practice·2026
Same author

Data-Driven Insights into Hyperkinetic Disorders in Neurodevelopmental Syndromes and Epileptic Encephalopathies.

Movement disorders clinical practice·2026
Same author

Activity-dependent adaptive deep brain stimulation improves gait in Parkinson's disease.

Nature medicine·2026
Same author

Late diagnosis of RAPSN mutation-associated congenital myasthenic syndrome with obstructive sleep apnea in a 5-year-old girl.

BMC pediatrics·2026
Same author

Altered structural connectivity in epilepsy with myoclonic atonic seizures.

Epilepsy research·2026
Same author

Association of glomerular hyperfiltration with mortality in stroke: an analysis using pooled individual patient data.

European stroke journal·2026

Related Experiment Video

Updated: Jan 16, 2026

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.9K

Managing Dystonia in Partington Syndrome.

Emilie Pichon1, Aurea Alioth2, Sabina Catalano Chiuvé2

  • 1Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.

Movement Disorders Clinical Practice
|September 30, 2025
PubMed
Summary

Partington syndrome treatment remains challenging, with limited options for hand dystonia. Current research suggests mild benefits from levodopa (l-dopa) and baclofen, but further studies are essential for effective patient management.

Keywords:
Aristaless‐related homeobox (ARX) genePartingtondystoniatreatment“Geste antagoniste”

More Related Videos

Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia
10:05

Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia

Published on: January 27, 2018

10.2K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.4K

Related Experiment Videos

Last Updated: Jan 16, 2026

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.9K
Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia
10:05

Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia

Published on: January 27, 2018

10.2K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.4K

Area of Science:

  • Neurology
  • Genetics
  • Movement Disorders

Background:

  • Partington syndrome is characterized by bilateral focal hand dystonia, intellectual disability, and oromotor dyspraxia.
  • The Aristaless-related homeobox (ARX) gene is implicated in Partington syndrome.
  • Effective treatments for the focal dystonia in Partington syndrome are not well-established, leading to management uncertainty.

Purpose of the Study:

  • To investigate treatment options for focal hand dystonia in Partington syndrome.
  • To evaluate the efficacy of various pharmacological and non-pharmacological interventions.

Main Methods:

  • Presentation of two clinical cases of Partington syndrome with ARX gene mutations.
  • Administration of multiple drug trials including levodopa (l-dopa), trihexyphenidyl, tetrabenazine, and benzodiazepines.
  • Use of botulinum toxin and a blinded dystonia protocol to assess l-dopa efficacy in one patient.
  • Systematic literature review of existing treatment studies.

Main Results:

  • Levodopa (l-dopa) showed only mild benefit in one patient under a blinded protocol.
  • Literature review suggests potential mild improvement with l-dopa and baclofen.
  • Propranolol, gabapentin, and haloperidol were reported as ineffective in previous studies.
  • Existing literature provides imprecise descriptions and mild improvement data, hindering definitive conclusions.

Conclusions:

  • Treatment options for Partington syndrome-associated dystonia are currently limited and elusive.
  • Further research, including additional case studies, is necessary.
  • Comprehensive characterization of Partington syndrome clinical features and effective treatment identification are critical.